Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Calcium Hydroxide Versus Triple Antibiotic Paste for Pain After Root Canal Treatment

2 de noviembre de 2026 actualizado por: Muzdalfa hanif, Rehman Medical Institute - RMI

Comparative Evaluation of Calcium Hydroxide and Triple Antibiotic Paste on Postoperative Pain in Teeth With Symptomatic Apical Periodontitis: A Randomized Clinical Trial

The goal of this clinical trial is to learn whether triple antibiotic paste reduces pain after root canal treatment more than calcium hydroxide in adults aged 18 to 70 years who have a dead (necrotic) tooth with painful infection at the root tip (symptomatic apical periodontitis). The main question it aims to answer is:

Does placing triple antibiotic paste inside the root canal lower pain 72 hours after treatment compared with calcium hydroxide?

Researchers will compare triple antibiotic paste (a mix of three antibiotics: ciprofloxacin, metronidazole and minocycline) with calcium hydroxide, the medicine most commonly placed inside root canals between dental visits, to see which one leads to less pain after treatment.

Participants will Receive root canal cleaning and shaping of the affected tooth Have either calcium hydroxide or triple antibiotic paste placed inside the root canal, decided by chance Rate their pain on a 0 to 10 scale 72 hours after treatment

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Pain after root canal treatment is common in teeth with symptomatic apical periodontitis and is linked to bacteria and their by-products remaining in the complex root canal system. Calcium hydroxide is widely used as an inter-appointment intracanal medicament because of its high alkalinity and antibacterial action, but some bacteria commonly found in infected root canals are resistant to it. Triple antibiotic paste combines ciprofloxacin, metronidazole and minocycline. Together they act against Gram-positive, Gram-negative and anaerobic bacteria, which may reduce the remaining bacterial load and periapical inflammation more effectively.

This is a two-arm, parallel-group randomized clinical trial conducted at the Department of Operative Dentistry and Endodontics, Rehman Medical Institute, Peshawar, Pakistan. Patients are recruited consecutively. Written informed consent is obtained from each patient or guardian. Baseline age, sex, tooth treated and preoperative pain are recorded on a standardized proforma.

Participants are allocated in a 1:1 ratio to the calcium hydroxide group (Group A) or the triple antibiotic paste group (Group B) by permuted block randomization with a block size of 4. The sequence is computer-generated. Allocation is concealed in sequentially numbered, opaque, sealed envelopes opened only after the patient's enrolment.

All teeth receive the same treatment under local anaesthesia and rubber dam isolation. The working length is set with an electronic apex locator and confirmed radiographically. Canals are cleaned and shaped with a rotary nickel-titanium system (ProTaper Gold, Dentsply Sirona) and irrigated with 2.5% sodium hypochlorite. The smear layer is removed with 17% EDTA for 1 minute, followed by a final saline rinse, to improve penetration of the medicament into dentinal tubules. Canals are dried with paper points.

Group A receives calcium hydroxide paste (Metapex or equivalent commercial preparation). Group B receives triple antibiotic paste made from ciprofloxacin, metronidazole and minocycline in a 1:1:1 ratio, mixed with propylene glycol to a creamy consistency. The medicament is placed with a lentulo spiral to working length, and the access cavity is sealed with a sterile cotton pellet and a temporary restoration (Cavit, 3M ESPE). The medicament stays in place for 7 days until the next appointment.

Pain is recorded by the patient on a 0 to 10 Visual Analog Scale at 72 hours after treatment and grouped as no pain (0), mild (1 to 3), moderate (4 to 6) or severe (7 to 10). The sample size of 138 patients (69 per group) was calculated with reference to Narayanan et al. (2022). Data are analysed in SPSS. Mean pain scores are compared between groups with the independent-samples t-test, and pain categories with the chi-square test. Pain category is also stratified by age and gender. A p-value below 0.05 is considered significant.

Your manuscript lists these as two separate steps: EDTA rinse and then medicament placement. Paste the next set of form questions when you reach them.

Tipo de estudio

Intervencionista

Inscripción (Actual)

138

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Peshawar, Pakistán
        • Rehman Medical Institute

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients aged 18 to 70 years
  • Both males and females
  • Teeth with pulp necrosis and a clinical diagnosis of symptomatic apical periodontitis
  • Teeth with a closed apex and fully developed roots
  • Willing to give written informed consent

Exclusion Criteria:

  • Use of antibiotics or analgesics in the 24 hours before treatment
  • Previous root canal treatment on the involved tooth
  • Teeth with anatomical anomalies, root resorption or incomplete root formation
  • Pregnant or breastfeeding women

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Calcium Hydroxide

Participants received calcium hydroxide paste as the intracanal medicament after cleaning, shaping and EDTA smear-layer removal. The paste was left in the canal for 7 days.

Calcium hydroxide paste placed in the root canal with a lentulo spiral to working length as an inter-appointment intracanal medicament.

Experimental: Triple Antibiotic Paste

Participants received triple antibiotic paste (ciprofloxacin, metronidazole and minocycline, 1:1:1, mixed with propylene glycol) as the intracanal medicament after cleaning, shaping and EDTA smear-layer removal. The paste was left in the canal for 7 days.

Equal parts ciprofloxacin, metronidazole and minocycline mixed with propylene glycol, placed in the root canal with a lentulo spiral to working length as an inter-appointment intracanal medicament.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Postoperative Pain Intensity
Periodo de tiempo: 72 hours after treatment

Pain intensity was self-reported by participants on a 0 to 10 Visual Analog Scale, where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain. Mean scores were compared between the calcium hydroxide and triple antibiotic paste groups.

72 hours after treatment

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Postoperative Pain Severity Category
Periodo de tiempo: 72 hours after treatment

Number of participants in each pain category, based on the 0 to 10 Visual Analog Scale score: no pain (0), mild (1 to 3), moderate (4 to 6) and severe (7 to 10). Proportions were compared between groups.

72 hours after treatment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de febrero de 2026

Finalización primaria (Actual)

14 de agosto de 2026

Finalización del estudio (Actual)

26 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

2 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Publicado por primera vez (Actual)

6 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • ERC/2025/123

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .